Furthermore, molecular docking analysis and subsequent co‐IP and pressure myograph experiments indicated that both Thonningianin A and Carfilzomib efficiently restored the GPR35‐TRPV4 interaction, preventing endothelial dysfunction and vasodilation impairment. Here, TRPV4 is linked to endothelial dysfunction.